Search Result
Results for "
Arg-Gly-Asp
" in MedChemExpress (MCE) Product Catalog:
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-12290
-
|
RGDS peptide; Fibronectin tetrapeptide
|
Integrin
|
Inflammation/Immunology
|
|
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
|
-
-
- HY-P0295
-
|
GRGDS
|
Integrin
|
Others
|
|
Gly-Arg-Gly-Asp-Ser (GRGDS) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ～5 and ～6.5 μM
|
-
-
- HY-P5021
-
|
c(RGDfE)
|
Biochemical Assay Reagents
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research .
|
-
-
- HY-P5038
-
|
c(GRGDSP)
|
Integrin
|
Cancer
|
|
Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells .
|
-
-
- HY-P4896
-
|
|
Integrin
|
Cancer
|
|
FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an integrin inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .
|
-
-
- HY-P0322
-
|
EMD 56574
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
|
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
|
-
-
- HY-126402
-
|
|
Integrin
|
Cancer
|
|
Arg-Gly-Asp (RGD) is a synthetic peptide corresponding to the cell adhesion sequence for the integrins αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α8β1, and α5β1. It is a component of radioligands and peptidomimetics that have been used in the study of integrin expression and activity in vivo.
|
-
-
- HY-12290A
-
|
RGDS peptide TFA; Fibronectin tetrapeptide TFA
|
Integrin
|
Inflammation/Immunology
|
|
Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1 .
|
-
-
- HY-P0295A
-
|
GRGDS TFA
|
Integrin
|
Inflammation/Immunology
|
|
Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin . Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ∼5 and ∼6.5 μM .
|
-
-
- HY-P3227
-
|
XJ735
|
Integrin
|
Inflammation/Immunology
|
|
Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension
Research .
|
-
-
- HY-P0322A
-
|
EMD 56574 TFA
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
|
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
|
-
-
- HY-P1613
-
|
Cyclo(RGDfV); C(RGDfV)
|
Integrin
Apoptosis
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .
|
-
-
- HY-P5025
-
|
Azido-c(RGDyK)
|
Drug Intermediate
|
Others
|
|
Cyclo(Arg-Gly-Asp-D-Tyr-ε-azido-Nle) (Azido-c(RGDyK)) is a polypeptide composed of arginine, glycine, aspartic acid, and tyrosine that can be used for Synthesis of [ 18F]FPyKYNE-c(RGDyK) .
|
-
-
- HY-P2300
-
|
Cyclo(RGDfC)
|
Integrin
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
|
-
-
- HY-P2300A
-
|
Cyclo(RGDfC) TFA
|
Integrin
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .
|
-
-
- HY-P1613A
-
|
Cyclo(RGDfV) TFA; C(RGDfV) TFA
|
Integrin
Apoptosis
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .
|
-
-
- HY-P4320
-
|
|
Integrin
|
Cancer
|
|
Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge:cys1-cys10), a decapeptide containing a cyclic RGD active sequence, is an Integrin αIIbβ3 antagonist that inhibits platelet and Adhesion of proMMP-13 .
|
-
-
- HY-P10303
-
|
Cyclo[RGDfK(Azide)]
|
Biochemical Assay Reagents
|
Others
|
|
Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)] is the derivative of Cyclo(-RGDfK) (HY-P0023). Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)] is a click chemistry reagent containing an azide group. Click chemistry has great potential for use in binding between nucleic acids, lipids, proteins, and other molecules, and has been used in many research fields because of its beneficial characteristics, including high yield, high specificity, and simplicity .
|
-
![Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)]](//file.medchemexpress.eu/product_pic/hy-p10303.gif)
-
- HY-P0178
-
|
|
Integrin
|
Inflammation/Immunology
|
|
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
|
-
-
- HY-P0178A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
|
-
-
- HY-P3732
-
|
|
Integrin
|
Cancer
|
|
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
|
-
-
- HY-P0309
-
|
|
Integrin
|
Cancer
|
|
Arg-Gly-Glu-Ser is a polypeptide related to RGD and is a negative control for Arg-Gly-Asp-Ser (HY-12290) .
|
-
-
- HY-P0309A
-
-
-
- HY-P1816
-
|
|
Integrin
|
Cancer
|
|
The connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. Fibronectin CS1 Peptide lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models .
|
-
-
- HY-P5098
-
|
|
Integrin
|
Cancer
|
|
E(c(RGDfK)) is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDfK)) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research .
|
-
-
- HY-P0278A
-
|
|
Integrin
|
Cancer
|
|
RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.
|
-
-
- HY-P0278
-
RGD
Maximum Cited Publications
6 Publications Verification
|
Integrin
|
Cancer
|
|
RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
|
-
-
- HY-P1921
-
-
-
- HY-P1740
-
|
|
Integrin
Apoptosis
Caspase
|
Inflammation/Immunology
|
|
RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
|
-
-
- HY-P1740A
-
|
|
Integrin
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .
|
-
-
- HY-P0290
-
GRGDSP
5 Publications Verification
|
Integrin
|
Cancer
|
|
GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
|
-
-
- HY-P2219
-
-
-
- HY-P2219A
-
-
-
- HY-P0290A
-
-
-
- HY-P5840
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Cyclo(RGDyC) is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer .
|
-
-
- HY-P10732
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-P10667
-
|
|
Integrin
|
Cancer
|
|
Ac-MRGDH-NH2 is a pentapeptide containing the RGD sequence. Ac-MRGDH-NH2 can be used to synthesize the diastereoisomeric prodrugs Λ- and Δ-[Ru(Ph2phen)2(κS,κN-(Ac-MRGDH-NH2))]Cl2. In these prodrugs, Ac-MRGDH-NH2 serves as a photolabile protecting group for the cytotoxic bis-aqua ruthenium warhead [Ru(Ph2phen)2(OH2)2]2+, and Ac-MRGDH-NH2 possesses integrin targeting ability and photosubstitution properties. Therefore, Ac-MRGDH-NH2 can be utilized in research on tumor-targeted photodynamic activation chemotherapy (PACT) .
|
-
-
- HY-P1559A
-
-
-
- HY-P6022
-
|
|
Integrin
|
Others
|
|
G4RGDSP, Integrin-binding peptide is a cell integrin-binding peptide that targets integrin receptors. G4RGDSP, integrin-binding peptide is coupled to alginate to increase the viability of cells in the scaffold. G4RGDSP, integrin-binding peptide can be used as an extrudable carrier for chondrocyte delivery for the study of 3D printing technology
|
-
-
- HY-P5287
-
|
|
Integrin
|
Cancer
|
|
cRGDfK-thioacetyl ester is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .
|
-
-
- HY-P5287A
-
|
|
Integrin
|
Cancer
|
|
cRGDfK-thioacetyl ester TFA is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .
|
-
-
- HY-P5053
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Integrin
|
Cancer
|
|
Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α?β? selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-P2635
-
|
|
Integrin
|
Cancer
|
|
RGDSPASSKP is a RGDS-containing fibronectin decapeptide .
|
-
-
- HY-P5251
-
-
-
- HY-125053A
-
|
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .
|
-
-
- HY-P0122
-
|
c(CRGDKGPDC)
|
Integrin
|
Cancer
|
|
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
|
-
-
- HY-125053
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes .
|
-
-
- HY-P5433F
-
|
|
Insulin Receptor
|
Others
|
|
IRS-1 Peptide, FAM labeled is a biological active peptide. (Insulin receptor substrate)
|
-
-
- HY-P10677
-
|
|
Integrin
|
Cancer
|
|
HB-3-20 leads to degradation of the cell surface integrin αVβ5. Transglutaminase 2 (TG2) has specificity for HB-3-20 (kcat/KM=0.16 μM -1min -1) .
|
-
-
- HY-P1654
-
|
|
Integrin
|
Cancer
|
|
A20FMDV2 is a selective αvβ6 integrin inhibitor (IC50: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from the foot-and-mouth disease virus. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .
|
-
- HY-P6010
-
|
|
Integrin
|
Cancer
|
|
αvβ6-BP is a selective αvβ6 binding peptide, and can be used for molecular imaging .
|
-
- HY-P10911
-
|
|
LDLR
|
Others
|
|
IETP2 targets low-density lipoprotein receptor-related protein 1 (LRP1) with a KD of 738 nM and can be used for drug- and imaging agents delivery across the blood-labyrinth barrier (BLB) .
|
-
- HY-P0316A
-
|
|
Thrombin
NO Synthase
|
Cardiovascular Disease
|
|
TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues .
|
-
- HY-P6009
-
|
|
Integrin
|
Cancer
|
|
Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide .
|
-
- HY-P0316
-
|
|
Thrombin
NO Synthase
|
Cardiovascular Disease
|
|
TP508 is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 activates endothelial cells and stem cells to revascularize and regenerate tissues .
|
-
- HY-P6010A
-
|
|
Integrin
|
Cancer
|
|
αvβ6-BP TFA is a selective αvβ6 binding peptide, and can be used for research of molecular imaging .
|
-
- HY-P6009A
-
|
|
Integrin
|
Cancer
|
|
Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide .
|
-
- HY-P5071
-
|
|
Bacterial
|
Infection
|
|
EcAMP3 is a hairpin-like peptide. EcAMP3 has antifungal and antibacterial activity. EcAMPs precursor family contains seven identical cysteine motifs: C1XXXC2(11–13)C3XXXC4 .
|
-
- HY-P5285
-
|
|
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Lunasin is a bioactive peptide with antioxidant, anti-inflammatory, anticancer and anti-aging properties. Lunasin can be isolated from soybean. Lunasin also has an epigenetic mechanism of action associated with histone acetylation. Lunasin can be internalized into cells and inhibit Oncosphere formation in cancer cells .
|
-
- HY-P5818
-
-
- HY-P5156
-
|
|
Potassium Channel
|
Neurological Disease
|
|
BDS-I known as blood depressing substance, is a marine toxin which can be extracted from Anemonia sulcata. BDS-I is a specific inhibitor of Potassium Channel, targeting to Kv3.4. BDS-I inhibits Aβ1-42-induced enhancement of KV3.4 activity, caspase-3 activation, and abnormal nuclear morphology of NGF-differentiated PC-12 cells. BDS-I reverts the Aβ peptide-induced cell death .
|
-
- HY-P1189
-
|
|
Integrin
|
Metabolic Disease
Inflammation/Immunology
|
|
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
|
-
- HY-P1189A
-
|
|
Integrin
|
Metabolic Disease
Inflammation/Immunology
|
|
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-12290
-
|
RGDS peptide; Fibronectin tetrapeptide
|
Integrin
|
Inflammation/Immunology
|
|
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
|
-
- HY-P0314A
-
|
|
Peptides
|
Cardiovascular Disease
|
|
Arg-Gly-Asp-Cys TFA is the binding motif of fibronectin to cell adhesion molecules. Arg-Gly-Asp-Cys TFA can inhibit platelet aggregation and fibrinogen binding .
|
-
- HY-P0295
-
|
GRGDS
|
Integrin
|
Others
|
|
Gly-Arg-Gly-Asp-Ser (GRGDS) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ～5 and ～6.5 μM
|
-
- HY-P5021
-
|
c(RGDfE)
|
Biochemical Assay Reagents
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research .
|
-
- HY-P4258
-
|
|
Peptides
|
Others
|
|
Arg-Gly-Asp-Ser-Pro is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-12290A
-
|
RGDS peptide TFA; Fibronectin tetrapeptide TFA
|
Integrin
|
Inflammation/Immunology
|
|
Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1 .
|
-
- HY-P0314
-
|
|
Peptides
|
Others
|
|
Arg-Gly-Asp-Cys is the binding motif of fibronectin to cell adhesion molecules, and can inhibit platelet aggregation and fibrinogen binding.
|
-
- HY-P4233
-
|
|
Peptides
|
Cancer
|
|
Gly-Arg-Gly-Asp-Ser-NH2 is a pentapeptide with no N-terminal modification. Gly-Arg-Gly-Asp-Ser-NH2 can be coupled to carrriers .
|
-
- HY-P0295A
-
|
GRGDS TFA
|
Integrin
|
Inflammation/Immunology
|
|
Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin . Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ∼5 and ∼6.5 μM .
|
-
- HY-P3227
-
|
XJ735
|
Integrin
|
Inflammation/Immunology
|
|
Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension
Research .
|
-
- HY-P5038
-
|
c(GRGDSP)
|
Integrin
|
Cancer
|
|
Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells .
|
-
- HY-P4896
-
|
|
Integrin
|
Cancer
|
|
FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an integrin inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .
|
-
- HY-P4945
-
|
|
Peptides
|
Others
|
|
Biotinyl-(εAhx)-Gly-Arg-Gly-Asp-Ser is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P0322
-
|
EMD 56574
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
|
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
|
-
- HY-P0322A
-
|
EMD 56574 TFA
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
|
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
|
-
- HY-P1613
-
|
Cyclo(RGDfV); C(RGDfV)
|
Integrin
Apoptosis
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .
|
-
- HY-P5025
-
|
Azido-c(RGDyK)
|
Drug Intermediate
|
Others
|
|
Cyclo(Arg-Gly-Asp-D-Tyr-ε-azido-Nle) (Azido-c(RGDyK)) is a polypeptide composed of arginine, glycine, aspartic acid, and tyrosine that can be used for Synthesis of [ 18F]FPyKYNE-c(RGDyK) .
|
-
- HY-P2300
-
|
Cyclo(RGDfC)
|
Integrin
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
|
-
- HY-P2300A
-
|
Cyclo(RGDfC) TFA
|
Integrin
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .
|
-
- HY-P1613A
-
|
Cyclo(RGDfV) TFA; C(RGDfV) TFA
|
Integrin
Apoptosis
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .
|
-
- HY-P4320
-
|
|
Integrin
|
Cancer
|
|
Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge:cys1-cys10), a decapeptide containing a cyclic RGD active sequence, is an Integrin αIIbβ3 antagonist that inhibits platelet and Adhesion of proMMP-13 .
|
-
- HY-P10303
-
|
Cyclo[RGDfK(Azide)]
|
Biochemical Assay Reagents
|
Others
|
|
Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)] is the derivative of Cyclo(-RGDfK) (HY-P0023). Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)] is a click chemistry reagent containing an azide group. Click chemistry has great potential for use in binding between nucleic acids, lipids, proteins, and other molecules, and has been used in many research fields because of its beneficial characteristics, including high yield, high specificity, and simplicity .
|
-
- HY-P0178
-
|
|
Integrin
|
Inflammation/Immunology
|
|
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
|
-
- HY-P0178A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
|
-
- HY-P3732
-
|
|
Integrin
|
Cancer
|
|
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
|
-
- HY-P0309
-
|
|
Integrin
|
Cancer
|
|
Arg-Gly-Glu-Ser is a polypeptide related to RGD and is a negative control for Arg-Gly-Asp-Ser (HY-12290) .
|
-
- HY-P0309A
-
-
- HY-P1816
-
|
|
Integrin
|
Cancer
|
|
The connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. Fibronectin CS1 Peptide lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models .
|
-
- HY-P5098
-
|
|
Integrin
|
Cancer
|
|
E(c(RGDfK)) is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDfK)) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research .
|
-
- HY-P0278A
-
|
|
Integrin
|
Cancer
|
|
RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.
|
-
- HY-P0278
-
RGD
Maximum Cited Publications
6 Publications Verification
|
Integrin
|
Cancer
|
|
RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
|
-
- HY-P1921
-
-
- HY-P1740
-
|
|
Integrin
Apoptosis
Caspase
|
Inflammation/Immunology
|
|
RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
|
-
- HY-P1740A
-
|
|
Integrin
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .
|
-
- HY-P0290
-
GRGDSP
5 Publications Verification
|
Integrin
|
Cancer
|
|
GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
|
-
- HY-P2219
-
-
- HY-P2219A
-
-
- HY-P0290A
-
-
- HY-P5840A
-
|
|
Peptides
|
Cancer
|
|
Cyclo(RGDyC) TFA is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) TFA can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer .
|
-
- HY-P5840
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Cyclo(RGDyC) is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer .
|
-
- HY-P10667
-
|
|
Integrin
|
Cancer
|
|
Ac-MRGDH-NH2 is a pentapeptide containing the RGD sequence. Ac-MRGDH-NH2 can be used to synthesize the diastereoisomeric prodrugs Λ- and Δ-[Ru(Ph2phen)2(κS,κN-(Ac-MRGDH-NH2))]Cl2. In these prodrugs, Ac-MRGDH-NH2 serves as a photolabile protecting group for the cytotoxic bis-aqua ruthenium warhead [Ru(Ph2phen)2(OH2)2]2+, and Ac-MRGDH-NH2 possesses integrin targeting ability and photosubstitution properties. Therefore, Ac-MRGDH-NH2 can be utilized in research on tumor-targeted photodynamic activation chemotherapy (PACT) .
|
-
- HY-P1559A
-
-
- HY-P10715
-
|
|
Peptides
|
Inflammation/Immunology
Cancer
|
|
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research .
|
-
- HY-P6022
-
|
|
Integrin
|
Others
|
|
G4RGDSP, Integrin-binding peptide is a cell integrin-binding peptide that targets integrin receptors. G4RGDSP, integrin-binding peptide is coupled to alginate to increase the viability of cells in the scaffold. G4RGDSP, integrin-binding peptide can be used as an extrudable carrier for chondrocyte delivery for the study of 3D printing technology
|
-
- HY-P1711
-
|
|
Peptides
|
Cardiovascular Disease
|
|
L 366763 is a potent peptide that acts as a fibrinogen receptor antagonist, preventing collagen-induced platelet aggregation and adhesion. L 366763 inhibits platelet deposition and maintains blood flow in a baboon thrombosis model, significantly prolonging bleeding time. L 366763 has antithrombotic efficacy, whereas recombinant LAPP does not have the same effect .
|
-
- HY-P5287
-
|
|
Integrin
|
Cancer
|
|
cRGDfK-thioacetyl ester is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .
|
-
- HY-P5287A
-
|
|
Integrin
|
Cancer
|
|
cRGDfK-thioacetyl ester TFA is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .
|
-
- HY-P0122B
-
|
|
Peptides
|
Cancer
|
|
iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers agents deep into extravascular tumor tissue. iRGD peptide 1 TFA has anti-metastatic activity .
|
-
- HY-P5053
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Integrin
|
Cancer
|
|
Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α?β? selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P2635
-
|
|
Integrin
|
Cancer
|
|
RGDSPASSKP is a RGDS-containing fibronectin decapeptide .
|
- HY-P5251
-
- HY-125053A
-
|
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .
|
- HY-P0122
-
|
c(CRGDKGPDC)
|
Integrin
|
Cancer
|
|
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
|
- HY-125053
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes .
|
- HY-P5257
-
|
CG-EDP3
|
Peptides
|
Others
|
|
Oligopeptide-24 (CG-EDP3) s a bioactive peptide with skin repair effect and has been reported used as a cosmetic ingredient .
|
- HY-P3525
-
|
|
Peptides
|
Others
|
|
G-Pen-GRGDSPCA is a polypeptide. G-Pen-GRGDSPCA can be used for the research of various biochemical studies .
|
- HY-P5433
-
|
|
Peptides
|
Others
|
|
IRS1-derived peptide is a biological active peptide. (This is a peptide fragment (979-989) of the insulin receptor substrate-1 containing the sequence motif YMXM known to bind to the two domains of SH2 on the 85kDa subunit of phosphoinositide 3-kinase.)
|
- HY-P5433F
-
|
|
Insulin Receptor
|
Others
|
|
IRS-1 Peptide, FAM labeled is a biological active peptide. (Insulin receptor substrate)
|
- HY-P10677
-
|
|
Integrin
|
Cancer
|
|
HB-3-20 leads to degradation of the cell surface integrin αVβ5. Transglutaminase 2 (TG2) has specificity for HB-3-20 (kcat/KM=0.16 μM -1min -1) .
|
- HY-P5350
-
|
|
Peptides
|
Others
|
|
FN-A208 is a biological active peptide. (This peptide is a fusion of A208, derived from murine laminin a1, and the active site of fibronectin (GRGDS), with a glycine spacer. This peptide forms amyloid-like fibrils and promotes formation of actin stress fibers that mediate fibroblast cell attachment, offering it potential as a bioadhesive for tissue regeneration and engineering. FN-A208 interacts with IKVAV receptors and integrins. Its activity is disrupted by the presence of EDTA.)
|
- HY-P1654
-
|
|
Integrin
|
Cancer
|
|
A20FMDV2 is a selective αvβ6 integrin inhibitor (IC50: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from the foot-and-mouth disease virus. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .
|
- HY-P6010
-
|
|
Integrin
|
Cancer
|
|
αvβ6-BP is a selective αvβ6 binding peptide, and can be used for molecular imaging .
|
- HY-P10911
-
|
|
LDLR
|
Others
|
|
IETP2 targets low-density lipoprotein receptor-related protein 1 (LRP1) with a KD of 738 nM and can be used for drug- and imaging agents delivery across the blood-labyrinth barrier (BLB) .
|
- HY-P0316A
-
|
|
Thrombin
NO Synthase
|
Cardiovascular Disease
|
|
TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues .
|
- HY-P2633
-
|
AC-100
|
Peptides
|
Metabolic Disease
|
|
Dentonin (AC-100) is a synthetic fragment derived from MEPE. Dentonin enhances osteogenesis by promoting osteoprogenitor adhesion and facilitates immature adherent cells survival. Dentonin has no significant effect to mature osteoblasts. Dentonin can be used for the research of phosphate homeostasis and bone metabolism .
|
- HY-P6009
-
|
|
Integrin
|
Cancer
|
|
Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide .
|
- HY-P0316
-
|
|
Thrombin
NO Synthase
|
Cardiovascular Disease
|
|
TP508 is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 activates endothelial cells and stem cells to revascularize and regenerate tissues .
|
- HY-P6010A
-
|
|
Integrin
|
Cancer
|
|
αvβ6-BP TFA is a selective αvβ6 binding peptide, and can be used for research of molecular imaging .
|
- HY-P10621
-
- HY-P6009A
-
|
|
Integrin
|
Cancer
|
|
Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide .
|
- HY-P10324
-
|
p16INK4a peptide
|
Peptides
|
Cancer
|
|
TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early G phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex .
|
- HY-P5071
-
|
|
Bacterial
|
Infection
|
|
EcAMP3 is a hairpin-like peptide. EcAMP3 has antifungal and antibacterial activity. EcAMPs precursor family contains seven identical cysteine motifs: C1XXXC2(11–13)C3XXXC4 .
|
- HY-P5285
-
|
|
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Lunasin is a bioactive peptide with antioxidant, anti-inflammatory, anticancer and anti-aging properties. Lunasin can be isolated from soybean. Lunasin also has an epigenetic mechanism of action associated with histone acetylation. Lunasin can be internalized into cells and inhibit Oncosphere formation in cancer cells .
|
- HY-P4903
-
|
|
Peptides
|
Cancer
|
|
RGD-targeted Proapoptotic Peptide is a peptide. The C-terminal RGD-4C peptide (ACDCRGDCFC) binds preferentially to integrins at sites of tumor angiogenesis.
|
- HY-P5818
-
- HY-P5156
-
|
|
Potassium Channel
|
Neurological Disease
|
|
BDS-I known as blood depressing substance, is a marine toxin which can be extracted from Anemonia sulcata. BDS-I is a specific inhibitor of Potassium Channel, targeting to Kv3.4. BDS-I inhibits Aβ1-42-induced enhancement of KV3.4 activity, caspase-3 activation, and abnormal nuclear morphology of NGF-differentiated PC-12 cells. BDS-I reverts the Aβ peptide-induced cell death .
|
- HY-P1189
-
|
|
Integrin
|
Metabolic Disease
Inflammation/Immunology
|
|
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
|
- HY-P1189A
-
|
|
Integrin
|
Metabolic Disease
Inflammation/Immunology
|
|
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-P10324
-
|
|
|
TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early G phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-P10303
-
|
Cyclo[RGDfK(Azide)]
|
|
Azide
|
|
Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)] is the derivative of Cyclo(-RGDfK) (HY-P0023). Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)] is a click chemistry reagent containing an azide group. Click chemistry has great potential for use in binding between nucleic acids, lipids, proteins, and other molecules, and has been used in many research fields because of its beneficial characteristics, including high yield, high specificity, and simplicity .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)]](http://file.medchemexpress.eu/product_pic/hy-p10303.gif)
